REVIEW ARTICLE
Year : 2014  |  Volume : 5  |  Issue : 4  |  Page : 227-231

Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon


1 Department of Internal Medicine, The Commonwealth Medical College, Scranton, Pennsylvania, USA
2 Department of Anesthesiology and Intensive Care Medicine, Gian Sagar Medical College, Patiala, Punjab, India
3 Department of Internal Medicine, Wright Center, Scranton, Pennsylvania, USA
4 Department of Emergency Medicine, Regional Hospital of Scranton, Scranton, Pennsylvania, USA

Correspondence Address:
Sukhminder Jit Singh Bajwa
House No -27-A, Ratan Nagar, Tripuri, Patiala, Punjab
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0976-500X.142428

Rights and Permissions

Canagliflozin is the first available oral inhibitor of sodium/glucose cotransporter 2 (SGLT2) in the market. At the outset it sounds excellent for the use in the elderly diabetic population, because of its minimal tendency to cause hypoglycemia. However, the clinician needs to exercise caution as it needs to be dosed renally. The clinician needs to be circumspect about potential drug interactions, especially when there is an underlying chronic kidney disease (CKD) and congestive heart failure (CHF). Also its use is best avoided in people who are predisposed to genital mycotic and urinary tract infections (UTI).


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3257    
    Printed79    
    Emailed1    
    PDF Downloaded2990    
    Comments [Add]    
    Cited by others 6    

Recommend this journal